B. Dunning

发表

Alpha cell function in health and disease: influence of glucagon-like peptide-1

J. Foley, B. Ahrén, B. Dunning, 2005, Diabetologia.

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

S. Schwartz, B. Dunning, P. Hollander, 2001, Diabetes care.

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

M. Taskinen, J. Foley, B. Dunning, 2006, Diabetologia.

Differential effects of short and long duration insulinotropic agents on meal‐related glucose excursions

B. Dunning, C. D. de Souza, P. Russo, 2001, Diabetes, obesity & metabolism.

New non-sulfonylurea insulin secretagogues.

B. Dunning, 1997, Expert opinion on investigational drugs.

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

J. Holst, R. DeFronzo, K. Cusi, 2007, The Journal of clinical endocrinology and metabolism.

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia *

P. Nilsson, W. Scherbaum, A. Mari, 2008, Diabetes, obesity & metabolism.

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

P. Nilsson, W. Scherbaum, A. Mari, 2008, The Journal of clinical endocrinology and metabolism.

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

J. Holst, A. Mari, Yan-Ling He, 2005, The Journal of clinical endocrinology and metabolism.

Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K(ATP) channels.

B. Dunning, S. Hu, S. Wang, 1999, The Journal of pharmacology and experimental therapeutics.

Modulation of insulin and glucagon secretion from the perfused rat pancreas by the neurohypophysial hormones and by desamino-D-arginine vasopressin (DDAVP)

B. Dunning, C. P. Fawcett, J. H. Moltz, 1984, Peptides.

Actions of neurohypophysial peptides on pancreatic hormone release.

B. Dunning, C. P. Fawcett, J. H. Moltz, 1984, The American journal of physiology.

Galanin release during pancreatic nerve stimulation is sufficient to influence islet function.

B. Dunning, G. Taborsky, 1989, The American journal of physiology.

The Role of (cid:1) -Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications

J. Gerich, B. Dunning, John E. Gerich, 2007 .

Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans

S. Dejager, J. Foley, B. Ahrén, 2011, Diabetes, obesity & metabolism.

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

P. Nilsson, M. Persson, S. Dejager, 2009, The Journal of clinical endocrinology and metabolism.

Patients with Type 2 Diabetes Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in

P. Nilsson, M. Persson, S. Dejager, 2009 .

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

J. Holst, Yan-Ling He, J. Foley, 2007, Journal of clinical pharmacology.

Glucosamine Inhibits Glucokinase In Vitro and Produces a Glucose-Specific Impairment of In Vivo Insulin Secretion in Rats

B. Balkan, B. Dunning, B. Balkan, 1994, Diabetes.

Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia

B. Dunning, J. Foley, R. Deacon, 2003, Diabetologia.

Portal glucose infusion exerts an incretin effect associated with changes in pancreatic neural activity in conscious dogs.

A. Cherrington, B. Dunning, M. Scott, 2002, Metabolism: clinical and experimental.

The Effect of Food on the Oral Bioavailability and the Pharmacodynamic Actions of the Insulinotropic Agent Nateglinide in Healthy Subjects

B. Dunning, A. Karara, J. McLeod, 1999, Journal of clinical pharmacology.

Galanin—Sympathetic Neurotransmitter in Endocrine Pancreas?

B. Dunning, G. Taborsky, 1988, Diabetes.

Clinical measures of islet function: usefulness to characterize defects in diabetes.

R. Pratley, J. Foley, B. Ahrén, 1993, Current diabetes reviews.

Alpha 2-adrenergic regulation of galanin and norepinephrine release from canine pancreas.

A. Scheurink, B. Dunning, G. Taborsky, 1992, The American journal of physiology.

Lactate clamp: a method to measure lactate utilization in vivo.

B. Dunning, J. Foley, M. A. Islam, 1998, The American journal of physiology.

Lactate clamp: a method to measure lactate utilization in vivo.

B. Dunning, M. A. Islam, Jiaping Gao, 1998, American journal of physiology. Endocrinology and metabolism.

Pancreatic noradrenergic nerves are activated by neuroglucopenia but not by hypotension or hypoxia in the dog. Evidence for stress-specific and regionally selective activation of the sympathetic nervous system.

B. Dunning, G. Taborsky, P. Havel, 1988, The Journal of clinical investigation.

Neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP), but not galanin, are autonomic cotransmitters in the porcine pancreas

J. Holst, B. Dunning, S. Sheikh, 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.

Glucose-dependent and Glucose-sensitizing Insulinotropic Effect of Nateglinide: Comparison to Sulfonylureas and Repaglinide

B. Dunning, Shiling Hu, Shuya Wang, 2001, International journal of experimental diabetes research.

Corelease of galanin and NE from pancreatic sympathetic nerves during severe hypoglycemia in dogs.

B. Dunning, G. Taborsky, P. Havel, 1992, The American journal of physiology.

Role for Autonomic Nervous System to Increase Pancreatic Glucagon Secretion During Marked Insulin-Induced Hypoglycemia in Dogs

B. Dunning, G. Taborsky, P. Havel, 1991, Diabetes.

Neural control of islet function by norepinephrine and sympathetic neuropeptides.

B. Dunning, G. Taborsky, 1991, Advances in experimental medicine and biology.

Nonadrenergic sympathetic neural influences on basal pancreatic hormone secretion.

B. Ahrén, B. Dunning, G. Taborsky, 1988, The American journal of physiology.

Galanin of the homologous species inhibits insulin secretion in the rat and in the pig.

B. Ahrén, B. Dunning, G. Taborsky, 1990, Acta physiologica Scandinavica.

Pancreatic and extrapancreatic galanin release during sympathetic neural activation.

B. Dunning, G. Taborsky, P. Havel, 1990, The American journal of physiology.

Galanin: a novel pancreatic neuropeptide.

F. Sundler, B. Ahrén, B. Dunning, 1986, The American journal of physiology.

Calcitonin gene-related peptide: a potent and selective stimulator of gastrointestinal somatostatin secretion.

B. Dunning, G. Taborsky, Beth E. Dunning, 1987, Endocrinology.

Contribution of galanin to stress-induced impairment of insulin secretion in swimming mice.

B. Ahrén, B. Dunning, S. Karlsson, 1991, Acta physiologica Scandinavica.

Human galanin: Primary structure and indentification of two molecular forms

J. Holst, P. Højrup, J. Andreasen, 1991, FEBS letters.

Galanin is co-localized with noradrenaline and neuropeptide Y in dog pancreas and celiac ganglion

F. Sundler, B. Ahrén, B. Dunning, 1990, Cell and Tissue Research.

Evidence that vasoactive intestinal polypeptide is a parasympathetic neurotransmitter in the endocrine pancreas in dogs

D. Baskin, C. Verchere, B. Dunning, 1997, Regulatory Peptides.

The presence and actions of NPY in the canine endocrine pancreas

F. Sundler, B. Ahrén, B. Dunning, 1987, Regulatory Peptides.

Galanin-immunoreactive nerves in the mouse and rat pancreas

F. Sundler, B. Ahrén, B. Dunning, 1991, Cell and Tissue Research.

Extraction of epinephrine and norepinephrine by the dog pancreas in vivo.

B. Ahrén, B. Dunning, G. Taborsky, 1988, Metabolism: clinical and experimental.

Somatostatin-28 does not regulate islet function in the dog.

B. Dunning, G. Taborsky, L. Klaff, 1988, Endocrinology.

Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes

J. Holst, D. Kelley, J. Foley, 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Effectiveness of Nateglinide on In Vitro Insulin Secretion from Rat Pancreatic Islets Desensitized to Sulfonylureas

B. Dunning, Shiling Hu, Shuya Wang, 2001, International journal of experimental diabetes research.

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications.

J. Gerich, B. Dunning, 2007, Endocrine reviews.

Presence of galanin in human pancreatic nerves and inhibition of insulin secretion from isolated human islets

F. Sundler, B. Ahrén, B. Dunning, 1991, Cell and Tissue Research.

Tissue-specific reduction of galanin content in the pancreas in alloxan diabetes in the mouse.

B. Ahrén, B. Dunning, 1993, Acta physiologica Scandinavica.

Reduced Pancreatic Content of the Inhibitory Neurotransmitter Galanin in Genetically Obese, Hyperinsulinemic Mice

B. Ahrén, B. Dunning, 1992, Pancreas.

Direct quantification of norepinephrine spillover and hormone output from the pancreas of the conscious dog.

A. Cherrington, B. Dunning, M. Scott, 1997, The American journal of physiology.

Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes

M. Persson, S. Dejager, J. Foley, 2008 .

Muscarinic stimulation maintains in vivo insulin secretion in response to glucose after prolonged hyperglycemia.

B. Dunning, B. Balkan, 1995, The American journal of physiology.

1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

T. Hughes, B. Dunning, M. Mone, 2002, Journal of medicinal chemistry.

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.

T. Hughes, B. Dunning, Kapa Prasad, 2003, Journal of medicinal chemistry.

Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.

R. Schmitz, S. Geisse, B. Dunning, 2000, The Journal of pharmacology and experimental therapeutics.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

R. Pratley, Yan-Ling He, J. Foley, 2009, The Journal of clinical endocrinology and metabolism.

Pharmacological Strategies for Reduction of Lipid Availability

B. Dunning, J. Foley, R. Deems, 1997, Annals of the New York Academy of Sciences.

Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes

Michael Camilleri, Adrian Vella, Robert A Rizza, 2007, Diabetes.

Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.

R. Pratley, B. Dunning, J. Foley, 2001, Current pharmaceutical design.

Nateglinide, but not glyburide, selectively enhances early insulin release and more effectively controls post-meal glucose excursions with less total insulin exposure

S. Schwartz, B. Dunning, M. Gatlin, 2000 .

The Canine Sympathetic Neuropeptide Galanin: A Neurotransmitter in Pancreas, A Neuromodulator in Liver

D. Baskin, B. Ahrén, C. Verchere, 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

The mechanisms underlying the unique pharmacodynamics of nateglinide

B. Dunning, S. Hu, B. Boettcher, 2003, Diabetologia.